Gujarat Terce Laboratories Ltd.

BSE: 524314 SECTOR: Pharmaceuticals & Drugs  4126   8   0

21.49
+0.21 (0.99%)
BSE: Today, 11:30 AM

Price Summary

Today's High

₹ 21.7

Today's Low

₹ 21.05

52 Week High

₹ 43.4

52 Week Low

₹ 0

FinStar is Suspended!

FinStar can not be assigned to this company due to its dicey outlook and insufficient data. We will update the FinStar for this company as soon as the data is updated from its end.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

15.95 Cr.

Enterprise Value

22.61 Cr.

No. of Shares

0.74 Cr.

P/E

0

P/B

2.32

Face Value

₹ 10

Div. Yield

0 %

Book Value (TTM)

₹  9.25

CASH

0.01 Cr.

DEBT

6.67 Cr.

Promoter Holding

36.45 %

EPS (TTM)

₹  -2.25

Sales Growth

59.4%

ROE

10.77 %

ROCE

8.31%

Profit Growth

134.61 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Brands

These are the brands of Gujarat Terce Laboratories Ltd.

Vitfol Acolate Resplash Aziter Codimol TerfloraZ Tynol fungibeat

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year59.4%
3 Year8.95%
5 Year9.68%

Profit Growth

1 Year134.61%
3 Year26.34%
5 Year127.47%

ROE%

1 Year10.77%
3 Year-4.52%
5 Year-1.37%

ROCE %

1 Year8.31%
3 Year-0.77%
5 Year1.41%

Debt/Equity

0.7818

Price to Cash Flow

-35.97

Interest Cover Ratio

2.86184538653367

CFO/PAT (5 Yr. Avg.)

0

Share Holding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Mar 2023 36.45 0
Dec 2022 36.22 0
Sep 2022 36.22 0
Jun 2022 36.22 0
Mar 2022 36.22 0
Investors List
* Figures given above are % of equity capital

 Strengths

  • The company has an efficient Cash Conversion Cycle of 7.2215244293257 days.
  • The company has a strong degree of Operating leverage, Average Operating leverage stands at 5.19026059300584.

 Limitations

  • The company has shown a poor revenue growth of 8.95321940309664% for the Past 3 years.
  • Company has a poor ROE of -4.52026386392869% over the past 3 years.
  • Company has a poor ROCE of -0.771756652807523% over the past 3 years
  • Company has negative cash flow from operations of -0.4433.
  • The company has a low EBITDA margin of -0.741267061034366% over the past 5 years.

Quarterly Result (All Figures in Cr.)

PARTICULARS Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023
Net Sales 9.32 9.41 12.58 11.91 12.89
Total Expenditure 11.01 11.1 12.98 11.79 13.09
Operating Profit -1.69 -1.68 -0.41 0.12 -0.2
Other Income 0.09 0.07 0.1 0.08 0.1
Interest 0.15 0.2 0.22 0.14 0.17
Depreciation 0.12 0.07 0.07 0.07 0.16
Exceptional Items 0 0 0 0 0
Profit Before Tax -1.86 -1.88 -0.59 0 -0.42
Tax -0.2 0 0 0 -1.22
Profit After Tax -1.66 -1.88 -0.59 0 0.8
Adjusted EPS (Rs) -2.23 -2.54 -0.79 -0.01 1.08

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022
Net Sales 29.01 31.03 37.54 25.18 40.13
Total Expenditure 28.69 30.54 36.86 27.95 39.02
Operating Profit 0.32 0.49 0.68 -2.77 1.12
Other Income 0.41 0.32 0.29 0.8 0.31
Interest 0.23 0.25 0.29 0.39 0.4
Depreciation 0.19 0.21 0.24 0.18 0.28
Exceptional Items 0 0 0 0 0
Profit Before Tax 0.33 0.35 0.44 -2.53 0.75
Tax 0.05 -0.09 0.16 -0.01 -0.13
Net Profit 0.27 0.43 0.28 -2.52 0.87
Adjusted EPS (Rs.) 0.36 0.58 0.37 -3.4 1.18

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022
Equity and Liabilities
Share Capital 7.42 7.42 7.42 7.42 7.42
Total Reserves 2.98 3.41 3.69 0.24 1.11
Borrowings 0.16 0.13 0.16 0.42 2.3
Other N/C liabilities 1.79 1.71 1.79 1.9 3.04
Current liabilities 7.12 6.67 9.29 11.71 13.21
Total Liabilities 19.47 19.34 22.34 21.7 27.09
Assets
Net Block 1.88 2.06 2.29 2.45 4.29
Capital WIP 0 0 0 0 0
Intangible WIP 0 0 0 0 0
Investments 0.27 0.29 0.27 0.27 0.27
Loans & Advances 2.48 2.44 2.54 2.55 2.65
Other N/C Assets 5.32 5.32 5.33 4.4 4.4
Current Assets 9.52 9.22 11.91 12.02 15.48
Total Assets 19.47 19.34 22.34 21.7 27.09
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022
Profit from operations 0.33 0.35 0.44 -2.52 0.75
Adjustment 0.05 0.22 0.25 0.57 0.6
Changes in Assets & Liabilities 4.3 -1.04 -2.17 1.94 -1.69
Tax Paid -0.1 -0.13 -0.1 -0.15 -0.1
Operating Cash Flow 4.58 -0.61 -1.59 -0.16 -0.44
Investing Cash Flow 1.11 -0.13 -0.27 -0.42 -2.37
Financing Cash Flow -5.49 0.2 1.72 1.83 1.53
Net Cash Flow 0.2 -0.55 -0.14 1.24 -1.28

Corporate Actions

Investors Details

PARTICULARS Mar 2022% Jun 2022% Sep 2022% Dec 2022% Mar 2023%
Promoters 36.22 36.22 36.22 36.22 36.45
abundant trade lin... 14.50 14.50 14.50 14.50 14.50
prajapati manjulab... 12.49 12.49 12.49 12.49 12.49
natwarbhai parsott... 8.03 8.03 8.03 8.03 8.07
natwarbhai pursh... - - - - -
aalap natubhai pra... 0.55 0.55 0.55 0.55 0.65
amritbhai p. praja... 0.42 0.42 0.42 0.42 0.42
shobhanaben natvar... 0.22 0.22 0.22 0.22 0.22
shachi ravi oza - - - - 0.10
PARTICULARS Mar 2022% Jun 2022% Sep 2022% Dec 2022% Mar 2023%
Investors 63.78 63.78 63.78 63.78 63.55
satya prakash mitt... - 1.68 1.68 1.88 1.88
satya prakash mitt... 4.57 - - - -
neepaben pareshbha... - - - - -
pareshkumar dayalj... - - - - -
radhika rastogi 1.90 - 1.18 1.25 1.25
dheeraj kumar lohia 1.88 1.49 1.49 1.49 1.49
arvindbhai chaud... - - - - -
nipaben pareshkuma... - - - - -
shaileshbhai praja... - - - - -
mohammad ali - - - - -
rishabh negi - - - 1.01 1.01

Annual Reports

Ratings & Research Reports

No Credit and Research reports exist for this company.Report us

Company Presentations

  • PresentationQ2FY22 9 Nov 2021
  • PresentationQ3FY22 1 Feb 2022

Guj. Terce Lab Stock Price Analysis and Quick Research Report. Is Guj. Terce Lab an attractive stock to invest in?

 

The Indian healthcare sector is expected to reach US$ 372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one of India’s largest sectors - both in terms of revenue and employment.

Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment. The structure of the healthcare delivery system in India consists of three broad segments: Primary care, Secondary care, and Tertiary care.

  • Primary care is the first point of contact between the population and the healthcare service providers. For example, Sub-center (SC), Primary Health Centre (PHC) and Community Health Centre (CHC) which is more relevant to rural areas (PHC’s).
  • Secondary care providers inpatient as well as outpatient medical services and includes simple surgical procedures. For example, District level & Mid-sized hospitals.
  • Tertiary care is the third level of the healthcare delivery system in the country. These hospitals are specialized consultative healthcare infrastructure. For example, Single specialty and Multi-specialty hospitals.

While healthcare services are offered by the public as well as private sectors, in urban as well as rural areas, generally people prefer private hospitals over public hospitals for treatment of diseases, illness, and sickness. So, let’s look into Guj. Terce Lab and its performance over the period of time.

  • Operating cash flow ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. Its cash from the operating activity was Rs -0.4433 Cr.
     
  • Financial Strength: Health care organizations usually have high debt loads and low equity capital in their balance sheet. So, Debt to Equity ratio is important to analyze the company’s sustainability. Guj. Terce Lab has a Debt to Equity ratio of 0.7818 , which is a strong indication for the company.
     
  • EPS growth: Investors should ensure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the company. In Guj. Terce Lab , the EPS growth was 134.613119773878 % which is good for the company.
     
  • Operating profit margin: It determines a company's potential earnings. It assesses how well-managed a company with respect to its basic overhead costs and other operating expenses, Guj. Terce Lab has OPM of 2.78444299927492 % which is a bad sign for profitability.
     
  • ROE: Guj. Terce Lab have a average ROE of 10.7715959817983 %. ROE is an important financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholder's fund is used for generating profits.
Brief about Guj. Terce Lab

X